Pharmaceutical company Novo Nordisk reports that the US Food and Drug Administration (FDA) has approved a tablet form of the weight-loss medication Wegovy. It ushers in a new era for weight-loss medications as the first tablet of its sort to be approved by the regulator.
According to Novo Nordisk, the Danish manufacturer of Wegovy, the once-daily pill would offer the same weight loss as the injection and was a “convenient option” to the injectable. It follows the FDA’s approval of Wegovy particularly for weight loss.
Others, such as Ozempic, were mainly approved for the treatment of Type 2 diabetes and have comparable weight-loss effects. During Novo Nordisk’s trials, the Wegovy pill demonstrated an average weight loss of 16.6%, the company reported on Monday.
The study also reported that, in the same study, one-third of the approximately 1,300 participants lost 20% or more of their body weight. Early January 2026 is when the pill is anticipated to be introduced in the United States. Patients will have a simple once-daily pill that will assist them lose as much weight as the original Wegovy injection,” stated CEO Mike Doustdar.
Also Read:
South Korea and The UK Reach a Trade Agreement
In Texas, a Deadly Measles Outbreak Does little to Dispel Vaccine Skepticism
